Titre : Masoprocol

Masoprocol : Questions médicales fréquentes

Termes MeSH sélectionnés :

Communication

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment le masoprocol est-il diagnostiqué ?

Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions.
Masoprocol Diagnostic médical
#2

Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?

Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité.
Essais cliniques Évaluation des symptômes

Symptômes 2

#1

Quels symptômes le masoprocol peut-il traiter ?

Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés.
Inflammation Cancer de la peau
#2

Le masoprocol provoque-t-il des effets secondaires ?

Oui, des effets secondaires comme des irritations cutanées peuvent survenir.
Effets secondaires Irritation cutanée

Prévention 2

#1

Le masoprocol peut-il prévenir des maladies ?

Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes.
Prévention des maladies Traitement
#2

Quelles mesures préventives sont recommandées avec le masoprocol ?

Éviter l'exposition excessive au soleil et suivre les conseils médicaux.
Prévention Exposition au soleil

Traitements 2

#1

Dans quel type de traitement le masoprocol est-il utilisé ?

Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés.
Traitement topique Lésions cutanées
#2

Comment le masoprocol est-il administré ?

Il est généralement appliqué localement sous forme de crème ou de gel.
Administration locale Crème

Complications 2

#1

Quelles complications peuvent survenir avec le masoprocol ?

Des complications comme des infections cutanées peuvent survenir en cas d'irritation.
Complications Infections cutanées
#2

Le masoprocol peut-il interagir avec d'autres médicaments ?

Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin.
Interactions médicamenteuses Consultation médicale

Facteurs de risque 2

#1

Qui est à risque d'effets secondaires du masoprocol ?

Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque.
Facteurs de risque Allergies cutanées
#2

Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?

Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation.
Immunodépression Surveillance médicale
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Masoprocol : Questions médicales les plus fréquentes", "headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-01", "dateModified": "2025-03-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Masoprocol" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Catéchols", "url": "https://questionsmedicales.fr/mesh/D002396", "about": { "@type": "MedicalCondition", "name": "Catéchols", "code": { "@type": "MedicalCode", "code": "D002396", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D02.455.426.559.389.657.166" } } }, "about": { "@type": "MedicalCondition", "name": "Masoprocol", "alternateName": "Masoprocol", "code": { "@type": "MedicalCode", "code": "D009637", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Mohammed Baqur S Al-Shuhaib", "url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib", "affiliation": { "@type": "Organization", "name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq." } }, { "@type": "Person", "name": "Sarfaraz Alam", "url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam", "affiliation": { "@type": "Organization", "name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland." } }, { "@type": "Person", "name": "Salman Ali Khan", "url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan", "affiliation": { "@type": "Organization", "name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan." } }, { "@type": "Person", "name": "Hayder O Hashim", "url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim", "affiliation": { "@type": "Organization", "name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq." } }, { "@type": "Person", "name": "Daniel H Obayes", "url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes", "affiliation": { "@type": "Organization", "name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Communication Overload in Hospitals: Exploring Organizational Safety Communication, Worker Job Attitudes, and Communication Efficacy.", "datePublished": "2022-09-29", "url": "https://questionsmedicales.fr/article/36172847", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/10410236.2022.2129313" } }, { "@type": "ScholarlyArticle", "name": "Strategic communication as planned behavior for science and risk communication: A theory-based approach to studying communicator choice.", "datePublished": "2022-09-18", "url": "https://questionsmedicales.fr/article/36116781", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/risa.14029" } }, { "@type": "ScholarlyArticle", "name": "Communication Openings: A Novel Approach for Serious Illness Communication in Homecare.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/37906048", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3928/00989134-20231011-02" } }, { "@type": "ScholarlyArticle", "name": "Everyday Barriers in Communicative Participation According to People With Communication Problems.", "datePublished": "2023-02-14", "url": "https://questionsmedicales.fr/article/36787154", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1044/2022_JSLHR-22-00405" } }, { "@type": "ScholarlyArticle", "name": "Beyond dyadic communication: Network of communication in inflammatory arthritis teams.", "datePublished": "2022-05-29", "url": "https://questionsmedicales.fr/article/35635126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/17423953221102629" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés chimiques organiques", "item": "https://questionsmedicales.fr/mesh/D009930" }, { "@type": "ListItem", "position": 3, "name": "Hydrocarbures", "item": "https://questionsmedicales.fr/mesh/D006838" }, { "@type": "ListItem", "position": 4, "name": "Hydrocarbures cycliques", "item": "https://questionsmedicales.fr/mesh/D006844" }, { "@type": "ListItem", "position": 5, "name": "Hydrocarbures aromatiques", "item": "https://questionsmedicales.fr/mesh/D006841" }, { "@type": "ListItem", "position": 6, "name": "Dérivés du benzène", "item": "https://questionsmedicales.fr/mesh/D001555" }, { "@type": "ListItem", "position": 7, "name": "Phénols", "item": "https://questionsmedicales.fr/mesh/D010636" }, { "@type": "ListItem", "position": 8, "name": "Catéchols", "item": "https://questionsmedicales.fr/mesh/D002396" }, { "@type": "ListItem", "position": 9, "name": "Masoprocol", "item": "https://questionsmedicales.fr/mesh/D009637" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Masoprocol - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Masoprocol", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Masoprocol", "description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?", "url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Communication#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Masoprocol", "description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?", "url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Communication#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Masoprocol", "description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?", "url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Communication#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Masoprocol", "description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?", "url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Communication#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Masoprocol", "description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?", "url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Communication#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Masoprocol", "description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?", "url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Communication#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le masoprocol est-il diagnostiqué ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité." } }, { "@type": "Question", "name": "Quels symptômes le masoprocol peut-il traiter ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés." } }, { "@type": "Question", "name": "Le masoprocol provoque-t-il des effets secondaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir." } }, { "@type": "Question", "name": "Le masoprocol peut-il prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes." } }, { "@type": "Question", "name": "Quelles mesures préventives sont recommandées avec le masoprocol ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux." } }, { "@type": "Question", "name": "Dans quel type de traitement le masoprocol est-il utilisé ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés." } }, { "@type": "Question", "name": "Comment le masoprocol est-il administré ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement appliqué localement sous forme de crème ou de gel." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le masoprocol ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation." } }, { "@type": "Question", "name": "Le masoprocol peut-il interagir avec d'autres médicaments ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires du masoprocol ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque." } }, { "@type": "Question", "name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 26/03/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Mohammed Baqur S Al-Shuhaib

1 publication dans cette catégorie

Affiliations :
  • Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq.
Publications dans "Masoprocol" :

Sarfaraz Alam

1 publication dans cette catégorie

Affiliations :
  • Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Publications dans "Masoprocol" :

Salman Ali Khan

1 publication dans cette catégorie

Affiliations :
  • Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Publications dans "Masoprocol" :

Hayder O Hashim

1 publication dans cette catégorie

Affiliations :
  • Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq.
Publications dans "Masoprocol" :

Daniel H Obayes

1 publication dans cette catégorie

Affiliations :
  • College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :

Jafar M B Al-Shuhaib

1 publication dans cette catégorie

Affiliations :
  • College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :

Sources (10000 au total)

Everyday Barriers in Communicative Participation According to People With Communication Problems.

The purpose of this study was to gain a comprehensive understanding of participation situations that are challenging for people with communication problems, to provide input for the further developmen... A purposive sampling strategy was used to include a diverse group of people with communication problems. Diaries were used as a sensitizing exercise for inductive in-depth interviews. In these intervi... Eighteen interviews yielded 44 different concepts. They were clustered in six themes, which capture the person, location, topic, mode, moment, and pace of communication. In total, 103 new items measur... This study resulted in an overview of self-reported barriers in daily communicative participation experienced by people with communication problems. These communicative participation situations can be...

Beyond dyadic communication: Network of communication in inflammatory arthritis teams.

To explore how communication is perceived and care is negotiated amongst IA healthcare teams by drawing on the perspectives of each team member.... This analysis drew on data from an ongoing three-year study exploring team-based IA care. We interviewed 11 participants including two men with IA and their family care providers and healthcare provid... Analysis revealed three themes regarding communication and care: (1) seeking/sharing information, (2) striving to coordinate unified care, and (3) providing patients a voice.... This study emphasizes the importance of understanding team dynamics beyond the dyad of patient and care provider. Negotiating power and decision-making in IA care is a dynamic process involving shifti...

Changes in the communicative skills of young people as a result of a communication training.

To analyze the effect of communication training developed for adolescents on the youth's communication skills.... Forty-one young people participated in the study and were divided into two groups. Group I received intervention - communication training for five weeks; Group II - were guided on the importance of vo... The analysis of questionnaires showed improvement in GI in two of the four skills assessed and no difference for GII. The video evaluations showed a significant difference between the groups in terms ... This study points out that the communication training method applied to young people might improve communicative skills, providing some insights into their communication strengths and potential areas ...

Effects of Aided Communication on Communicative Participation for People With Amyotrophic Lateral Sclerosis.

Many people with amyotrophic lateral sclerosis (PALS) experience speech changes, which may interfere with participation in communication situations. This study was designed to investigate the effects ... Participants with amyotrophic lateral sclerosis completed an online questionnaire in which they identified their current communication methods, rated their speech function, and rated their communicati... Communication aids appeared to support communicative participation for many participants with dysarthria. Across all levels of speech function, PALS who use aided communication reported better partici... Aided communication can help PALS continue to participate in various communication situations as their speech function deteriorates. Variability in self-rated communicative participation, even for PAL... https://doi.org/10.23641/asha.22782986....

Communication experiences of healthcare students whilst managing adults with communication disorders.

Research has found that people with communication disabilities are three times more likely to encounter medical mishaps. Almost a third of patients with speech-language therapy (SLT) diagnoses have ot... This study aims to describe the communication challenges and strategies employed by a group of final year Nursing, Medicine, Dietetics and Human Nutrition, Physiotherapy and Occupational Therapy stude... A qualitative, phenomenological study design was used. Questionnaires were electronically distributed, and results were analysed thematically.... The most significant challenges whilst managing adults with communication disorders were patients' receptive and expressive language difficulties. Further challenges included lack of knowledge surroun... This study revealed that there is a need to develop healthcare students' skills in managing adults with communication disorders. This is because of the challenges faced and inefficiency of the strateg...